Business

AbbVie to Invest $217 Million Modernizing Its Barceloneta, Puerto Rico Biologics Plant

Published Nov 18, 2026, 4:37 PM ASTvia Sin Comillas

At a glance

  • AbbVie plans to hire 100 people for the Barceloneta project, including engineers, scientists, manufacturing operators and laboratory technicians, with work starting this year and full operations expected by 2030.
  • AbbVie says it has committed more than $2.4 billion to U.S. manufacturing over the past 16 months and more than 1,400 jobs across North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico.
  • The Barceloneta project is part of a pledged $100 billion in research, development and capital investment in the United States over the next decade, the company says.

Why this matters: Barceloneta’s two AbbVie plants already employ more than 1,200 people, and the 100 new engineers, scientists and technicians would add to that payroll in a town whose economy leans heavily on pharmaceutical manufacturing.

AbbVie (NYSE: ABBV), a Chicago-based biopharmaceutical company, announced a new $217 million investment to modernize its biologics manufacturing plant in Barceloneta, Puerto Rico. The upgrade will integrate advanced manufacturing technologies with artificial intelligence to support production of AbbVie’s current and next-generation medicines for immunology and neuroscience. Construction will begin this year, and the facilities are expected to be fully operational by 2030.

AbbVie plans to hire 100 people, including engineers, scientists, manufacturing operators and laboratory technicians. The company says it has committed more than $2.4 billion to U.S. manufacturing over the past 16 months and plans to create more than 1,400 jobs in North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico. The project is part of AbbVie’s pledge to invest $100 billion in research and development and capital investments, including manufacturing, in the United States over the next decade.

Azita Saleki, AbbVie’s executive vice president and chief operating officer, said the company’s medicines are essential for patients and that its colleagues in Puerto Rico have long been fundamental to bringing treatments to patients. She said the investment reflects the company’s continued commitment to Puerto Rico and to strengthening its U.S. manufacturing network. AbbVie employs about 29,000 people in the United States, including more than 1,200 at its two Barceloneta plants.

In 2025 it announced the acquisition of Capstan Therapeutics for $2.1 billion, and since 2023 it has invested more than $20 billion in acquisitions after losing patent protection on Humira.

In context

SourceSin Comillas

More in Business